



# The Open Rheumatology Journal

Content list available at: <https://openrheumatologyjournal.com>



## CORRIGENDUM

### Clinical Efficacy and Safety of Leflunomide in Egyptian Patients with Active Rheumatoid Arthritis: CLEAR Interim Results

Adel El Sayed<sup>1,\*</sup>, Abd El-Monim Hilal<sup>2</sup>, Ahmed Abogamal<sup>3</sup>, Alaa Labeeb<sup>4</sup>, Amin Abdel Hamid<sup>3</sup>, Amira El Gerby<sup>2</sup>, Ayman Farouk Darwish<sup>5</sup>, Aziza Sayed Omar<sup>6</sup>, Dahlia Abdel Mohsen<sup>7</sup>, Dalia Faiez<sup>1</sup>, A M Abda<sup>8</sup>, Fatemah A. Elshabacy<sup>9</sup>, Manal Tayel<sup>10</sup>, Mohamed Elwakd<sup>11</sup>, Mohamed Mortada<sup>12</sup>, Mohsen H.Elshahaly<sup>6</sup>, Nevine Mohannad<sup>10</sup>, Raga A. Kader<sup>2</sup>, S. Z. Hassan<sup>11</sup>, Samah A. Elbakry<sup>7</sup> and Sherif Refaat<sup>13</sup>

<sup>1</sup>Department of Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt

<sup>2</sup>Rheumatology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt

<sup>3</sup>Rheumatology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt

<sup>4</sup>Rheumatology, Physical Medicine and Rehabilitation Department, Menoufia University, Al Minufiyah, Egypt

<sup>5</sup>Rheumatology & Rehabilitation Department, Minia University, Minia, Egypt

<sup>6</sup>Rheumatology, Physical Medicine & Rehabilitation Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

<sup>7</sup>Rheumatology & Internal Medicine Department, Ain Shams University, Cairo, Egypt

<sup>8</sup>Department of Rheumatology and Rehabilitation, Assiut University, Assiut, Egypt

<sup>9</sup>Rheumatology Department, Benha Teaching Hospital, Benha, Egypt

<sup>10</sup>Rheumatology & Internal Medicine Department, Alexandria University, Alexandria, Egypt

<sup>11</sup>Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt

<sup>12</sup>Rheumatology and Rehabilitation Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

<sup>13</sup>Rheumatology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt

#### Article History

Received: July 29, 2018

Revised: October 23, 2018

Accepted: December 19, 2018

#### Clinical Efficacy and Safety of Leflunomide in Egyptian Patients with Active Rheumatoid Arthritis: CLEAR Interim Results

The Open Rheumatology Journal, 2018, 12: 323-331

**The last paragraph on page 327 is revised as follows:**

In regards to patients receiving leflunomide as a first-line therapy, the mean  $\pm$ SD CDAI total score was significantly decreased ( $p < 0.001$ ) from  $35.40 \pm 16.49$  at baseline visit to reach  $15.04 \pm 9.63$  after 6 weeks from treatment initiation. After additional 6 weeks, further significant decrease ( $p = 0.028$ ) was observed in the mean  $\pm$ SD CDAI total score to reach  $11.83 \pm 5.88$ .

**The original paragraph provided is mentioned below:**

In regards to patients receiving leflunomide as a first-line therapy, the mean  $\pm$ SD CDAI total score was significantly decreased ( $p < 0.001$ ) from  $35.40 \pm 16.49$  at baseline visit to reach  $15.04 \pm 9.63$  after 6 weeks from treatment initiation, however after additional 6 weeks, the mean  $\pm$ SD CDAI total

score was insignificantly decreased ( $p = 0.028$ ) to be  $11.83 \pm 5.88$ .

**The first paragraph on page 328 is revised as follows:**

In a similar pattern, in patients receiving leflunomide as add-on therapy to other DMARDs with or without steroids, the mean  $\pm$ SD CDAI total score was significantly decreased ( $p < 0.001$ ) from  $37.09 \pm 14.12$  at baseline visit to reach  $20.42 \pm 9.36$  after 6 weeks from treatment initiation, and it was significantly further decreased ( $p < 0.001$ ) to reach  $15.98 \pm 10.32$  after additional 6 weeks.

**The original paragraph provided is mentioned below:**

In patients receiving leflunomide as add-on therapy to other DMARDs with or without steroids, the mean  $\pm$ SD CDAI total score was significantly decreased from  $37.09 \pm 14.12$  at baseline visit to reach  $20.42 \pm 9.36$  after 6 weeks from treatment initiation. Unlike patients receiving leflunomide as a first line therapy, in this group, the mean  $\pm$ SD CDAI total score was significantly further decreased to reach  $15.98 \pm 10.32$  after an additional 6 weeks.

© 2019 El Sayed *et al.*

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (<https://creativecommons.org/licenses/by/4.0/legalcode>). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.